DAX25.067 -0,2%Est506.270 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,1900 +2,0%Nas26.282 +0,3%Bitcoin56.174 +0,4%Euro1,1406 -0,1%Öl76,01 +0,1%Gold4.111 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SpaceX A42D4F Rheinmetall 703000 NVIDIA 918422 Deutsche Telekom 555750 Volkswagen (VW) vz. 766403 Infineon 623100 SAP 716460 Allianz 840400 BYD A0M4W9 Siemens Energy ENER6Y Carl Zeiss Meditec 531370 Lufthansa 823212 Microsoft 870747 Bayer BAY001 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Iran-Krieg im Blick: DAX geht schwächer ins Wochenende -- US-Börsen in Grün -- VW: Modellpalette soll schrumpfen -- SK hynix, SpaceX, Tesla, Meta, Bayer, Siemens Energy, DEUTZ, Plug Power im Fokus
Top News
Apple-Aktie im Fokus: Klage gegen OpenAI wegen gestohlener Firmengeheimnisse eingereicht Apple-Aktie im Fokus: Klage gegen OpenAI wegen gestohlener Firmengeheimnisse eingereicht
DHL-Aktie: Drastischer Anstieg der Reklamationen im ersten Halbjahr DHL-Aktie: Drastischer Anstieg der Reklamationen im ersten Halbjahr
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

UCB Aktie

Kaufen
Verkaufen
UCB Aktien-Sparplan
237,40 EUR -12,80 EUR -5,12 %
BMN
237,20 EUR -13,20 EUR -5,27 %
GVIE
finanzen.net zero
UCB jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.45,13 Mrd. EUR

KGV29,12Div. Rendite0,43%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN852738

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINBE0003739530

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolUCBJF

UCB Aktien News

DatumMeistgelesen
BenzingaUCB Data Reinforce Long-Term Promise For Weak Muscles Disorder
ZacksVeeva Expands Safety Suite Footprint With UCB Pharmacovigilance Deal
MotleyFoolUCB Q1 2026 Earnings Call Transcript
Wer­bungUCB-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
ZacksUCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know
MotleyFoolUnited Community Banks UCB Earnings Transcript
PR NewswireUCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
PR NewswireUCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
PR Newswire/C O R R E C T I O N -- UCB/
PR NewswireU.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
PR NewswireUCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
PR NewswireUCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
PR NewswireBIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireResults published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
ZacksRecent Price Trend in UCB (UCBJY) is Your Friend, Here's Why
PR NewswireBIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
PR NewswireBIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
PR NewswireGen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
ZacksUCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
ZacksAll You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy
ZacksHere's Why Momentum in UCB (UCBJY) Should Keep going
PR NewswireUCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
MotleyFoolUnited Community Banks UCB Earnings Transcript
ZacksUCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?
PR NewswireUCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
PR NewswireUCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
PR NewswireUCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
PR NewswireInaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
PR NewswireUCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
PR NewswireBIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireUCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
PR NewswireUCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
GlobeNewswireUCB Convening Notice to the General Meeting of the Shareholders 2025
PR NewswireNew data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
PR NewswireEpilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
PR NewswireBIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
PR NewswireBIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

UCB News

UCB News: auf dieser Seite finden Sie alle UCB News und Nachrichten zur UCB Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch UCB News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um UCB News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.